03549nas a2200289   4500000000100000008004100001260003400042653005700076653002100133653002800154653001700182100002100199700001300220700001400233700001500247700001400262700001400276700001700290700001200307700001600319245013600335856009300471300001400564490000700578520264900585022002503234       2023                            d  bOxford University Press (OUP)10aPublic Health, Environmental and Occupational Health10aGeneral Medicine10aHealth (social science)10aazithromycin1 aWamyil-Mshelia T1 aMadaki S1 aIsiyaku S1 aShu'aibu J1 aOlobio NP1 aAliero AA1 aAbdulsalam M1 aTaiwo J1 aMcDickoh VJ00aTreatment coverage of mass administration of azithromycin among children aged 1–11 months in 21 districts of Kebbi state, Nigeria  uhttps://academic.oup.com/inthealth/article-pdf/15/Supplement_2/ii12/53979153/ihad086.pdf  aii12-ii180 v153 a<p>Abstract</p>

<p>Background The WHO recommends mass drug administration (MDA) as a strategy to deliver safe and cost-effective medicines to prevent and treat diseases. The antibiotic, azithromycin, has been used during MDA for the treatment and prevention of trachoma in Nigeria. Azithromycin has recently been shown to reduce infant mortality in communities receiving it for trachoma-elimination purposes in sub-Saharan Africa. This article reports on the implementation strategies for the safety and antimicrobial resistance of mass administration of azithromycin to children aged 1–11 mo using the trachoma programme platform in Kebbi state. Methods The mass administration of azithromycin among 1–11-mo-olds in Kebbi was implemented in three phases: (i) the preimplementation phase, during which specific activities were conducted to achieve government and community buy-in, ownership and capacity building; (ii) the implementation phase, which included the mass administration of azithromycin carried out by community volunteers (also known as community-directed distributors [CDDs]), monitoring (by health workers and independent monitors) and reporting of the distribution by all personnel; and (iii) the postimplementation phase, which included the validation of community data, where each item of community summary data is verified and checked for completeness and accuracy before uploading to the District Health Information System platform, where data are visualised, analysed and stored. Results In total, 97% of the target population received treatment; the remaining 3% were not treated due to signs of ill health, history of allergy to antibiotics, parental refusal or absence at the time of MDA. Children aged 1–11 mo accounted for 17% of the under-5 population, with females constituting 56% of the target population. In communities that were monitored, reports showed that only 5% lacked distribution materials (scales, slings or registers), &amp;gt;80% correctly entered data into community registers and 5% of children were not treated due to inadequate azithromycin provided to the CDDs for distribution. Conclusion The implementation of azithromycin MDA for children aged 1–11 mo in Kebbi, utilising the trachoma platform, exhibited commendable coverage due to existing programme platform, healthcare and community structures, intensive advocacy and social mobilisation, real-time monitoring and progress-tracking strategies. It also demonstrated that the trachoma platform is suitable for implementing public health interventions, even after the elimination of trachoma in previously endemic districts.</p>
  a1876-3413, 1876-3405